CELLIVERY THERAPEUTICS INCCC

CELLIVERY THERAPEUTICS INC

16USDD
−7−30.43%
At close at Mar 9, 22:44 GMT
USD
No trades
See on Supercharts

268600 fundamentals

Key facts

Market capitalization
Founded2014
CEODae-Woong Cho
About

Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmaceutical products. Its products include improved cell-permeable parkin (iCP-Parkin), cell/tissue permeable frataxin (CP-FXN), improved cell-permeable SOCS3 (iCP-SOCS3), cell-permeable BMP2 (CP-BMP2), cell-permeable truncated SOCS3 (CP-SD), improved cell-permeable nuclear import inhibitor (iCP-NI), and others. The company was founded by Dae-Woong Cho on March 14, 2014 and is headquartered in Seoul, South Korea.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪3.00‬
‪6.00‬
‪9.00‬
‪12.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−97%‬
‪−89%‬
‪−81%‬
‪−73%‬
‪−65%‬
Q1 '24
Q2 '24
Q3 '24
‪‪−2.40 M‬‬
‪‪−1.20 M‬‬
‪0.00‬
‪‪1.20 M‬‬
‪‪2.40 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
No data available
There's currently no revenue data to show for the selected period.

Dividends

Dividend yield, history and sustainability

No dividends
268600 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−12.00 M‬‬
‪0.00‬
‪‪12.00 M‬‬
‪‪24.00 M‬‬
‪‪36.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
No data available
There's currently no assets and liabilities data to show.